| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary application of L-ANAP is as a fluorescent probe rather than a pharmacological agent. It is incorporated into target proteins at defined positions to report on local polarity, conformational dynamics, and ligand-induced structural changes. The acetylnaphthalene fluorophore exhibits a large Stokes shift and its emission spectrum shifts depending on the hydrophobicity of the local environment, making it useful for studying protein folding, membrane protein dynamics, and protein-protein interactions.
|
|---|---|
| ln Vitro |
L-ANAP is a fluorescent non-canonical amino acid that can be employed for customized fluorescence labeling [1]. L-ANAP is a genetically encoded and polarity-sensitive fluorescent unnatural amino acid (Uaa). Fluorescent UAAs, including L-dansylalanine, L-(7-hydroxycoumarin-4-yl)ethylglycine, and L-ANAP, are particularly essential for molecular and cell biology because they can complement and enhance a wide range of fluorescent protein (FP)[2].
In vitro, L-ANAP is used for site-specific labeling of recombinant proteins expressed in E. coli or mammalian cells. It is incorporated into proteins using an orthogonal tRNA/tRNA synthetase pair that recognizes the amber stop codon (UAG). The labeled proteins are purified and used for fluorescence spectroscopy, including steady-state and time-resolved fluorescence measurements, to study conformational changes and dynamics. |
| ln Vivo |
In vivo, L-ANAP has been used for imaging protein dynamics in live cells and organisms. It enables fluorescence-based monitoring of protein localization, trafficking, and interactions in real time. The polarity-sensitive nature of the probe allows detection of conformational changes in response to physiological stimuli. However, detailed in vivo pharmacology data are not applicable, as L-ANAP is a research tool for protein labeling rather than a therapeutic agent.
|
| Enzyme Assay |
For non-cellular assays, L-ANAP-labeled proteins are purified and characterized by fluorescence spectroscopy. Steady-state fluorescence spectra are recorded at excitation wavelengths of 350-380 nm, and emission spectra are collected from 400-600 nm. Fluorescence lifetime measurements are performed using time-correlated single photon counting (TCSPC). Anisotropy measurements assess rotational mobility and protein interactions.
|
| Cell Assay |
For cell-based assays, plasmids encoding the target protein with an amber codon at the desired position and the orthogonal tRNA/tRNA synthetase pair are co-transfected into cells. L-ANAP is added to the culture medium and incorporated into the protein during translation. Cells are imaged by fluorescence microscopy to visualize protein localization and dynamics. Fluorescence resonance energy transfer (FRET) experiments are performed to study protein-protein interactions.
|
| Animal Protocol |
For in vivo experiments, L-ANAP-labeled proteins can be expressed in transgenic organisms (e.g., C. elegans, Drosophila, zebrafish) using genetic code expansion technology. The fluorescent probe enables imaging of protein dynamics in live animals. However, detailed protocols depend on the specific protein and organism, and no standard in vivo pharmacology protocols exist for this research tool.
|
| References |
|
| Molecular Formula |
C15H16N2O3
|
|---|---|
| Molecular Weight |
272.29914
|
| Exact Mass |
272.116
|
| CAS # |
1313516-26-5
|
| Related CAS # |
L-ANAP hydrochloride;(±)-ANAP;1185251-08-4;(±)-ANAP hydrochloride;2308035-47-2
|
| PubChem CID |
72695021
|
| Appearance |
Light yellow to yellow solid
|
| LogP |
2.639
|
| tPSA |
92.42
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
372
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N[C@@H](CNC1=CC=C2C=C(C(C)=O)C=CC2=C1)C(O)=O
|
| InChi Key |
XKZCXMNMUMGDJG-AWEZNQCLSA-N
|
| InChi Code |
InChI=1S/C15H16N2O3/c1-9(18)10-2-3-12-7-13(5-4-11(12)6-10)17-8-14(16)15(19)20/h2-7,14,17H,8,16H2,1H3,(H,19,20)/t14-/m0/s1
|
| Chemical Name |
(2S)-3-[(6-acetylnaphthalen-2-yl)amino]-2-aminopropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | |
| 5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | |
| 10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.